Compare LAB & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAB | BETR |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance: Consumer Services |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.1M | 538.7M |
| IPO Year | 2008 | N/A |
| Metric | LAB | BETR |
|---|---|---|
| Price | $0.89 | $35.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.35 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 2.0M | 539.8K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,937,000.00 | N/A |
| Revenue This Year | N/A | $54.06 |
| Revenue Next Year | $2.63 | $66.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $10.81 |
| 52 Week High | $1.72 | $94.06 |
| Indicator | LAB | BETR |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 51.57 |
| Support Level | N/A | $26.89 |
| Resistance Level | $1.39 | $35.07 |
| Average True Range (ATR) | 0.04 | 3.39 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 18.13 | 33.23 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.